



Market Announcement

20 June 2022

Health House International Limited (ASX: HHI) – Trading Halt

Description

The securities of Health House International Limited ('HHI') will be placed in trading halt at the request of HHI, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Wednesday, 22 June 2022 or when the announcement is released to the market.

Issued by

Oma Murad

Adviser, Listings Compliance (Perth)

20 June 2022

Australian Securities Exchange Limited
40 Central Park
152 – 158 St Georges Terrace
PERTH WA 6000

Attention: Barbara Lim
By email only: Barbara.Lim@asx.com.au

Dear Madam,

TRADING HALT REQUEST

In accordance with ASX Listing Rule 17.1, Health House International Limited ('the Company', ASX: **HHI**) requests the granting of a trading halt in HHI's ordinary securities listed on the Australian Securities Exchange (ASX).

The Company provides the following information in relation to the request:

1. The trading halt is requested pending an announcement by the Company in relation to its Scheme Implementation Deed;
2. The Company requests an immediate trading halt and anticipates that the trading halt remain in place until the earlier of the commencement of trading on Wednesday, 22 June 2022 or the making of an announcement in respect to its Scheme Implementation Deed; and
3. HHI confirms that it is not aware of any reason why a trading halt should not be granted or any other information necessary to inform the market about the trading halt.

Yours sincerely



Tim Slate
Company Secretary

ABOUT HEALTH HOUSE

The Health House International Group is an international pharmaceutical distributor specialising in, but not limited to, the distribution of medicinal cannabis products across Australasia, United Kingdom and Europe.

The Group is a fully licenced and regulated specialised importer, exporter and distributor currently distributing medicinal cannabis products from 14 producers to pharmacies, prescribers, specialist medicinal cannabis clinics and researchers across Australasia. In the UK and Germany, the Group holds all relevant licences (including GMP manufacturing), Wholesale Dealers and Controlled Drugs licences. The Group supplies pharmacies, hospitals, government departments and other wholesalers with medicinal cannabis and general pharmaceutical products in the UK and Europe. The Group also integrates education of patients and healthcare professionals in the use of medicinal cannabis as a core part of its activities and is developing digital tools to enable a holistic understanding of usage.